US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Avalyn Pharma

27.95

-1.7800-5.99%

Post-market: 27.950.00000.00%19:34 EDT

Volume:139.59K

Turnover:4.00M

Market Cap:1.24B

PE:-13.10

High:30.26

Open:29.98

Low:27.84

Close:29.73

52wk High:33.32

52wk Low:24.15

Shares:44.33M

Float Shares:16.67M

Volume Ratio:0.48

T/O Rate:0.84%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.1330

EPS(LYR):-87.7434

ROE:-68.34%

ROA:-41.74%

PB:-4.69

PE(LYR):-0.32

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Avalyn Pharma completes target enrollment in MIST trial

Avalyn Pharma completes enrollment in Phase 2b MIST trial of inhaled pirfenidone for progressive pulmonary fibrosis

Avalyn Pharma - Topline Data From Mist Trial Expected in Second Half of 2027

THOMSON REUTERS

Avalyn Completes Target Enrollment in Phase 2B Mist Trial of AP01 (Inhaled Pirfenidone) for Patients With Progressive Pulmonary Fibrosis

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AVLN"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AVLN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVLN\",,,,,undefined,":{"symbol":"AVLN","market":"US","secType":"STK","nameCN":"Avalyn Pharma","latestPrice":27.95,"timestamp":1784923200000,"preClose":29.73,"halted":0,"volume":139587,"hourTrading":{"tag":"盘后","latestPrice":27.95,"preClose":27.95,"latestTime":"19:34 EDT","volume":3284,"amount":91787.99,"timestamp":1784936048366,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.059872182980154766,"floatShares":16666700,"shares":44333095,"eps":-2.133,"marketStatus":"Market Closed","change":-1.78,"latestTime":"07-24 16:00:00 EDT","open":29.98,"high":30.26,"low":27.84,"amount":3997142.14263,"amplitude":0.081399,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.133,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1785139200000},"marketStatusCode":7,"adr":0,"listingDate":1777521600000,"exchange":"NASDAQ","adjPreClose":29.73,"postHourTrading":{"tag":"盘后","latestPrice":27.95,"preClose":27.95,"latestTime":"19:34 EDT","volume":3284,"amount":91787.99,"timestamp":1784936048366,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.48365737207159654},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVLN\",,,,,undefined,":{"symbol":"AVLN","floatShares":16666700,"roa":"-41.74%","roe":"-68.34%","lyrEps":-87.743381,"volumeRatio":0.48365737207159654,"shares":44333095,"dividePrice":0,"high":30.26,"amplitude":0.081399,"preClose":29.73,"low":27.84,"week52Low":24.15,"pbRate":"-4.69","week52High":33.32,"institutionHeld":0,"latestPrice":27.95,"eps":-2.133,"divideRate":0,"volume":139587,"delay":0,"ttmEps":-2.133,"open":29.98,"prevYearClose":18,"prevWeekClose":28.3,"prevMonthClose":32.92,"prevQuarterClose":32.92,"fiveDayClose":28.3,"twentyDayClose":28.98,"sixtyDayClose":18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AVLN\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AVLN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AVLN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":4,"updateTime":1781755200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AVLN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AVLN","date":"2026-07-24","current":-13.10361,"percent":0.413793,"low":-16.179325,"twenty":-14.519455,"median":-13.774754,"eighty":-13.193732,"high":-8.833116,"avg":-13.804077,"sd":1.028642,"marketCap":1318022914},"quantilePoints":[{"date":"2026-05-01","current":-14.471589,"twenty":-13.343894,"median":-11.652352,"eighty":-9.960811,"marketCap":1233037266},{"date":"2026-05-08","current":-13.215324,"twenty":-14.430368,"median":-13.598092,"eighty":-13.264397,"marketCap":1125998425},{"date":"2026-05-15","current":-15.026112,"twenty":-14.666899,"median":-14.368536,"eighty":-13.42143,"marketCap":1280284879},{"date":"2026-05-22","current":-13.941602,"twenty":-14.643344,"median":-13.941602,"eighty":-13.42143,"marketCap":1187880255},{"date":"2026-05-29","current":-13.931787,"twenty":-14.643344,"median":-13.931787,"eighty":-13.215324,"marketCap":1187044014},{"date":"2026-06-05","current":-13.244767,"twenty":-14.510847,"median":-13.774754,"eighty":-13.102456,"marketCap":1128507148},{"date":"2026-06-12","current":-13.774754,"twenty":-14.471589,"median":-13.774754,"eighty":-13.161343,"marketCap":1173664159},{"date":"2026-06-18","current":-14.383258,"twenty":-14.479441,"median":-13.794383,"eighty":-13.204528,"marketCap":1225511097},{"date":"2026-06-26","current":-13.585419,"twenty":-14.649233,"median":-13.936694,"eighty":-13.238878,"marketCap":1284773093},{"date":"2026-07-02","current":-14.143275,"twenty":-14.655122,"median":-14.03484,"eighty":-13.265378,"marketCap":1337529476},{"date":"2026-07-10","current":-13.557292,"twenty":-14.643344,"median":-13.937009,"eighty":-13.265378,"marketCap":1282113107},{"date":"2026-07-17","current":-12.038425,"twenty":-14.576758,"median":-13.784568,"eighty":-13.15846,"marketCap":1138473879},{"date":"2026-07-24","current":-13.937009,"twenty":-14.519455,"median":-13.774754,"eighty":-13.193732,"marketCap":1318022914}],"updateTime":1785118600299},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AVLN\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2644450557","title":"Avalyn Pharma completes target enrollment in MIST trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2644450557","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644450557?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:15","pubTimestamp":1781698555,"startTime":"0","endTime":"0","summary":"Avalyn Pharma (AVLN) announced that it has completed target enrollment of 375 patients in the Phase 2b MIST clinical trial of AP01 in patients with...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/avalyn-pharma-completes-target-enrollment-in-mist-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/avalyn-pharma-completes-target-enrollment-in-mist-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVLN","BK4007","MIST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644745938","title":"Avalyn Pharma completes enrollment in Phase 2b MIST trial of inhaled pirfenidone for progressive pulmonary fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2644745938","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644745938?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:02","pubTimestamp":1781697779,"startTime":"0","endTime":"0","summary":"Avalyn Pharma completed target enrollment of 375 patients in the Phase 2b MIST trial of AP01 for progressive pulmonary fibrosis.Results have not been presented; topline data are expected in the second half of 2027.The study is designed to assess whether inhaled pirfenidone can better preserve lung function versus placebo over 52 weeks.Management cited earlier-stage data suggesting tolerability that could support longer time on therapy, a potential differentiator in the disease.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL6CpYww:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00B3QW5Z07.USD","BK4585","AVLN","BK4112","SG9999014005.SGD","IE00BN0W2W23.USD","NDAQ","LU2095319765.USD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","BK4588","IE00BGHQF748.EUR","LU0314104364.USD","IE00BKPKM429.USD","SG9999014039.USD","IE00BN0W2T93.GBP","SG9999014021.USD","LU2210149790.SGD","BK4007","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644745656","title":"Avalyn Pharma - Topline Data From Mist Trial Expected in Second Half of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2644745656","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644745656?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:00","pubTimestamp":1781697602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nTUA4X2JZZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVLN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644455937","title":"Avalyn Completes Target Enrollment in Phase 2B Mist Trial of AP01 (Inhaled Pirfenidone) for Patients With Progressive Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2644455937","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644455937?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:00","pubTimestamp":1781697602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nTUA4X2JZZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVLN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":10,"pageCount":1,"totalSize":37,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/AVLN\",params:#limit:6,delay:false,,,undefined,":[]}}